In last trading session, ARS Pharmaceuticals Inc (NASDAQ:SPRY) saw 1.53 million shares changing hands with its beta currently measuring 0.86. Company’s recent per share price level of $13.05 trading at $0.52 or 4.15% at ring of the bell on the day assigns it a market valuation of $1.28B. That closing price of SPRY’s stock is at a discount of -41.84% from its 52-week high price of $18.51 and is indicating a premium of 42.15% from its 52-week low price of $7.55. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.92 million shares which gives us an average trading volume of 1.57 million if we extend that period to 3-months.

For ARS Pharmaceuticals Inc (SPRY), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.36 in the current quarter.

ARS Pharmaceuticals Inc (NASDAQ:SPRY) trade information

Upright in the green during last session for gaining 4.15%, in the last five days SPRY remained trading in the green while hitting it’s week-highest on Wednesday, 04/02/25 when the stock touched $13.05 price level, adding 1.51% to its value on the day. ARS Pharmaceuticals Inc’s shares saw a change of 23.70% in year-to-date performance and have moved 3.57% in past 5-day. ARS Pharmaceuticals Inc (NASDAQ:SPRY) showed a performance of 24.17% in past 30-days. Number of shares sold short was 19.43 million shares which calculate 15.06 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 22 to the stock, which implies a rise of 40.68% to its current value. Analysts have been projecting 18 as a low price target for the stock while placing it at a high target of 30. It follows that stock’s current price would drop -37.93% in reaching the projected high whereas dropping to the targeted low would mean a loss of -37.93% for stock’s current value.

ARS Pharmaceuticals Inc (SPRY) estimates and forecasts

This year revenue growth is estimated to fall -6.80% from the last financial year’s standing.

6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 7.48M for the same. And 6 analysts are in estimates of company making revenue of 14.71M in the next quarter.

In 2025, company’s earnings growth rate is likely to be around -1764.10% while estimates for its earnings growth in next 5 years are of 43.97%.

ARS Pharmaceuticals Inc (NASDAQ:SPRY)’s Major holders

Insiders are in possession of 22.97% of company’s total shares while institution are holding 74.91 percent of that, with stock having share float percentage of 97.25%. Investors also watch the number of corporate investors in a company very closely, which is 74.91% institutions for ARS Pharmaceuticals Inc that are currently holding shares of the company. DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) is the top institutional holder at SPRY for having 11.08 million shares of worth $94.27 million. And as of 2024-06-30, it was holding 11.4409 of the company’s outstanding shares.

The second largest institutional holder is RA CAPITAL MANAGEMENT, L.P., which was holding about 10.86 million shares on 2024-06-30. The number of shares represents firm’s hold over 11.2168 of outstanding shares, having a total worth of $92.43 million.

On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.99 shares of worth $25.98 million or 2.03% of the total outstanding shares. The later fund manager was in possession of 1.49 shares on Feb 28, 2025 , making its stake of worth around $19.46 million in the company or a holder of 1.52% of company’s stock.